All In Biotech

Drug Trial Radar · NCT05734105

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated With Imatinib

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Dec 13, 2023

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Deciphera Pharmaceuticals, LLCIndustry
Sponsor type
Industry
First posted
Feb 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations. Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or discontinue sunitinib.

Conditions

  • GIST

Interventions

  • RipretinibDrug

    50 mg tablets

  • SunitinibDrug

    12.5 mg tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Up to end of treatment; up to approximately 48 months

Locations

70 sites in 15 countries. Site status is shown where the registry gives one.

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Yale University

    New Haven, Connecticut

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Boston Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • M Health Fairview University of Minnesota Medical Center

    Minneapolis, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Northwell Health Cancer Institute/ R.J. Zuckerberg Cancer Center

    New York, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Oregon Health & Science University

    Portland, Oregon

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Virginia

    Charlottesville, Virginia

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia

  • Alfred Health

    Melbourne, Victoria, Australia

  • INCA - Instituto Nacional de Cancer

    Rio de Janeiro, Rio de Janeiro, Brazil

  • CEPEN - Centro de Pesquisa e Ensino em Saude de Santa Catarina

    Florianópolis, Santa Catarina, Brazil

  • Hospital de Cancer de Barretos - Fundacao Pio XII

    Barretos, São Paulo, Brazil

  • Hospital Sirio-Libanes

    São Paulo, São Paulo, Brazil

  • Hospital 9 de Julho

    São Paulo, São Paulo, Brazil

  • AC Camargo Câncer Center

    São Paulo, São Paulo, Brazil

  • Arthur J.E. Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada

  • Juravinski Cancer Centre

    Hamilton, Ontario, Canada

  • University Health Network, Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Clínica San Carlos De Apoquindo Red Salud UC Christus

    Las Condes, RM, Chile

  • Centro de Oncología de Precisión

    Santiago, RM, Chile

  • Institut Bergonié

    Bordeaux, France

  • Centre Léon Bérard

    Lyon, France

  • Institut Gustave Roussy

    Villejuif, France

  • CHU Dijon

    Dijon, Bourgogone, France

  • Centre Eugène Marquis

    Rennes, Ille et Vilaine, France

  • Helios Klinikum Berlin-Buch

    Berlin, Germany

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.